Skip to main content
. 2019 Dec 11;267(4):1004–1011. doi: 10.1007/s00415-019-09667-5

Fig. 1.

Fig. 1

Rates of treatment-refractory MG and treatment-responsive MG according to subgroups suggested by Gilhus et al. [2]; AChR denotes acetylcholine receptor, MG Myasthenia gravis and MuSK muscle-specific tyrosine kinase